1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Dr Reddy's launches fentanyl transdermal patch in India

 
• By Anju Ghangurde

Dr Reddy's Laboratories has launched a fentanyl transdermal patch 25μg/hr and 50μg/hr (marketed as Finrid) in India. The product has been licensed from Sparsha Pharma, an Indian transdermal products firm, and is used in the management of severe to moderate pain. Finrid provides continuous systemic delivery of fentanyl, a potent opioid analgesic, for up to 72 hours.

Dr Reddy's Laboratories has launched a fentanyl transdermal patch 25μg/hr and 50μg/hr (marketed as Finrid) in India. The product has been licensed from Sparsha Pharma, an Indian transdermal products firm, and is used in the management of severe to moderate pain. Finrid provides continuous systemic delivery of fentanyl, a potent opioid analgesic, for up to 72 hours.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.